ArticleInternational journal of clinical and experimental medicine2015
Association of Leu125Val polymorphisms in the PECAM-1 gene with the risk of coronary heartdisease: a meta-analysis.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Association of PECAM-1 Gene Polymorphisms with Kawasaki Disease in Chinese Children.Disease markers · 2017Article
- Article
- PECAM-1 Leu125Val (rs688) Polymorphism and Diabetic Nephropathy in Caucasians with Type 2 Diabetes Mellitus.Analytical cellular pathology (Amsterdam) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSeveral published literatures investigated the relation between a polymorphism (Leul25Val) in platelet endothelial cell adhesion molecule-1 (PECAM-1) gene and risk of coronary heart disease (CHD) and did not reach the same conclusion. To shed light on these inconclusive findings, we performed a meta-analysis of studies relating the PECAM-1 genetic polymorphism (Leul25Val) to the risk of CHD.
methodsWe identified literatures by searching PubMed, EMBASE, Chinese National Knowledge Infrastructure databases (CNKI) and Wanfang database in China. Data from eligible studies were extracted for meta-analysis. CHD risk associated with PECAM-1 genetic polymorphism (Leul25Val) was estimated by pooled odds ratios (ORs) and 95% confidence intervals (95% CIs). The software Review Manager (Version 5.2) was used for meta-analysis. Publication bias was tested by funnel plot.
resultsA total of 15 studies comprising 3696 cases and 3940 controls fulfilled the inclusion criteria. Our results did not show that Leul25Val polymorphism in PECAM-1 gene was associated with the risk of CHD [(LL+LV) vs VV, OR = 1.15, 95% CI: 0.84-1.56, P = 0.38; (VV+LV) vs LL, OR = 0.96, 95% CI: 0.79-1.17, P = 0.69; V vs L, OR = 1.08, 95% CI: 0.92-1.27, P = 0.80, respectively] by a meta-analysis.
conclusionThe results of our meta-analysis suggested that Leul25Val polymorphism in PECAM-1 gene is not a susceptibility marker of CHD.
Indexed as
Identifiers
25932154PMC4402801W371473805What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.